Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
- 7 February 2023
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 259, 58-67
Abstract
No abstract availableKeywords
Funding Information
- Korea University Guro Hospital
- Hanyang University
- Boston Scientific Corporation
This publication has 22 references indexed in Scilit:
- Randomized Trial of Preventive Angioplasty in Myocardial InfarctionNew England Journal of Medicine, 2013
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive SummaryCirculation, 2013
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2012
- Culprit Vessel Only Versus Multivessel and Staged Percutaneous Coronary Intervention for Multivessel Disease in Patients Presenting With ST-Segment Elevation Myocardial InfarctionJACC, 2011
- Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial InfarctionJACC, 2011
- A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary StentJACC, 2011
- Impact of Multivessel Coronary Artery Disease and Noninfarct-Related Artery Revascularization on Outcome of Patients With ST-Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention (from the EUROTRANSFER Registry)The American Journal of Cardiology, 2010
- A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-upHeart, 2009
- Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarctionEuropean Heart Journal, 2007
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988